Intelligent Fingerprinting Drug Screening Video

November 20, 2023

Share This Video

INBS Announces Fiscal 2025 Second Quarter Financial Results

Intelligent Bio Solutions Announces Fiscal Q2 2025 Financial Results and Key Operational Achievements

Gross profit increase of 32.6% and 11-point gross profit margin increase driven by higher-margin cartridge sales Submitted FDA 510(k) and remain on track for planned expansion into multi-billion dollar U.S. market in 2025 Added strategic partnerships, increasing visibility across the Asia-Pacific Region and the U.S. Secured 19 accounts during quarter,

INBS Releases Shareholder Letter Detailing Growth and Expansion

Intelligent Bio Solutions Releases Shareholder Letter Detailing 2024 Growth and 2025 U.S. Expansion Strategy

Company highlights key milestones achieved in 2024, growing revenues and progress towards U.S. expansion in 2025 NEW YORK, February 10, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today issued a letter to shareholders from Harry